Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK JACOBS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1073515201
CMS profile
320570
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$48.34

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $18.00 1
Education $17.41 1
Food and Beverage $12.93 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
ASCEND Therapeutics US, LLC $18.00 1
PFIZER INC. $17.41 1
Avion Pharmaceuticals $12.93 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK JACOBS

NPI 1073515201 · CMS profile ID 320570

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073515201?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK JACOBS, NPI 1073515201, CMS profile ID 320570. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073515201?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARK JACOBS, NPI 1073515201, CMS profile ID 320570. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073515201?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARK JACOBS, NPI 1073515201, CMS profile ID 320570, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1073515201?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $48.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Avion Pharmaceuticals $12.9311/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845416327 CMS
PFIZER INC. $17.4106/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833275857 CMS
ASCEND Therapeutics US, LLC $18.0006/15/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828480399 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $430.40 19
PY2021 $48.34 3
PY2022 $27.90 2
PY2023 $39.87 2
PY2024 $38.67 2
PY2025 $62.17 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $345,577.55 114
PY2024 Principal investigator $486,201.91 190
PY2023 Principal investigator $631,878.39 124
PY2022 Principal investigator $520,630.07 107
PY2021 Principal investigator $450,776.15 37
PY2020 Principal investigator $223,012.49 5
PY2019 Principal investigator $169,685.50 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $250.00 12/08/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1030318019
Principal investigator 1 Exeltis, USA Inc. $2,315.24 12/07/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380037
Principal investigator 1 Exeltis, USA Inc. $12,204.90 12/07/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380699
Principal investigator 1 Abbott Laboratories $560.00 12/06/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039570345
Principal investigator 1 Sumitomo Pharma America, Inc. $1,141.25 11/22/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327889
Principal investigator 1 Sumitomo Pharma America, Inc. $4,177.50 11/22/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327895
Principal investigator 1 Abbott Laboratories $560.00 11/20/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039568661
Principal investigator 1 Abbott Laboratories $280.00 11/20/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039570339
Principal investigator 1 Sumitomo Pharma America, Inc. $1,097.50 11/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327853
Principal investigator 1 Sumitomo Pharma America, Inc. $12,076.25 11/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327859
Principal investigator 1 Sumitomo Pharma America, Inc. $2,209.64 11/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327865
Principal investigator 1 Sumitomo Pharma America, Inc. $550.00 11/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327871
Principal investigator 1 Sumitomo Pharma America, Inc. $6,607.13 11/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327877
Principal investigator 1 Sumitomo Pharma America, Inc. $658.13 11/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327883
Principal investigator 1 Exeltis, USA Inc. $500.00 11/10/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379817
Principal investigator 1 Exeltis, USA Inc. $5,504.60 11/10/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381903
Principal investigator 1 Exeltis, USA Inc. $9,048.60 11/09/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380301
Principal investigator 1 Sumitomo Pharma America, Inc. $4,191.18 11/09/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327821
Principal investigator 1 Sumitomo Pharma America, Inc. $3,572.50 11/09/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327827
Principal investigator 1 Sumitomo Pharma America, Inc. $1,196.25 11/09/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327833
Principal investigator 1 Sumitomo Pharma America, Inc. $1,759.98 11/09/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327839
Principal investigator 1 Sumitomo Pharma America, Inc. $700.00 11/09/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327847
Principal investigator 1 Exeltis, USA Inc. $300.00 11/02/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380939
Principal investigator 1 Exeltis, USA Inc. $425.00 10/26/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379645
Principal investigator 1 Exeltis, USA Inc. $9,975.00 10/26/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381231
Principal investigator 1 Exeltis, USA Inc. $6,300.00 10/19/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379215
Principal investigator 1 Exeltis, USA Inc. $225.00 10/19/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381245
Principal investigator 1 Sumitomo Pharma America, Inc. $6,673.75 10/19/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679997
Principal investigator 1 Exeltis, USA Inc. $500.00 10/13/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380523
Principal investigator 1 Exeltis, USA Inc. $8,542.10 10/13/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381001
Principal investigator 1 Exeltis, USA Inc. $12,868.20 10/11/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381047
Principal investigator 1 Sumitomo Pharma America, Inc. $959.50 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679923
Principal investigator 1 Sumitomo Pharma America, Inc. $841.25 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679929
Principal investigator 1 Sumitomo Pharma America, Inc. $885.50 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679935
Principal investigator 1 Sumitomo Pharma America, Inc. $6,111.25 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679941
Principal investigator 1 Sumitomo Pharma America, Inc. $217.50 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679947
Principal investigator 1 Sumitomo Pharma America, Inc. $2,160.00 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679953
Principal investigator 1 Sumitomo Pharma America, Inc. $10,401.25 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679959
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679967
Principal investigator 1 Sumitomo Pharma America, Inc. $411.50 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679973
Principal investigator 1 Sumitomo Pharma America, Inc. $649.00 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679979
Principal investigator 1 Sumitomo Pharma America, Inc. $262.50 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679985
Principal investigator 1 Sumitomo Pharma America, Inc. $3,123.00 10/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679991
Principal investigator 1 Sumitomo Pharma America, Inc. $1,621.13 09/26/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327815
Principal investigator 1 Sumitomo Pharma America, Inc. $5,750.00 09/22/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1030318001
Principal investigator 1 Sumitomo Pharma America, Inc. $1,000.00 09/22/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1030318007
Principal investigator 1 Sumitomo Pharma America, Inc. $1,005.00 09/22/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1030318013
Principal investigator 1 Sumitomo Pharma America, Inc. $3,268.13 09/21/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327789
Principal investigator 1 Sumitomo Pharma America, Inc. $2,610.00 09/21/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327795
Principal investigator 1 Sumitomo Pharma America, Inc. $1,848.38 09/21/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327801
Principal investigator 1 Sumitomo Pharma America, Inc. $1,805.62 09/21/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327809
Principal investigator 1 Exeltis, USA Inc. $42,930.50 09/14/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380771
Principal investigator 1 Exeltis, USA Inc. $7,390.13 09/13/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379985
Principal investigator 1 Abbott Laboratories $1,120.00 09/11/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039568649
Principal investigator 1 Exeltis, USA Inc. $2,086.20 09/07/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380041
Principal investigator 1 Abbott Laboratories $560.00 08/18/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039568655
Principal investigator 1 Abbott Laboratories $560.00 08/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039570333
Principal investigator 1 Exeltis, USA Inc. $3,028.51 08/10/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379515
Principal investigator 1 Exeltis, USA Inc. $24,962.40 08/10/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380539
Principal investigator 1 Sumitomo Pharma America, Inc. $492.74 07/27/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327783
Principal investigator 1 Exeltis, USA Inc. $500.00 07/21/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380383
Principal investigator 1 Exeltis, USA Inc. $1,000.00 07/14/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379603
Principal investigator 1 Sumitomo Pharma America, Inc. $46,945.21 07/13/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
SERENE No dispute reported 06/30/2026 1030327777
Principal investigator 1 Organon LLC $7,217.10 07/12/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
OG-6219-P001 No dispute reported 06/30/2026 1016081183
Principal investigator 1 Exeltis, USA Inc. $50.00 07/11/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380499
Principal investigator 1 Exeltis, USA Inc. $1,390.50 07/10/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379779
Principal investigator 1 Exeltis, USA Inc. $17,929.70 07/07/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379383
Principal investigator 1 Exeltis, USA Inc. $5,549.64 07/07/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379919
Principal investigator 1 Abbott Laboratories $9,672.30 06/27/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039570327
Principal investigator 1 Exeltis, USA Inc. $250.00 06/23/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051378927
Principal investigator 1 Exeltis, USA Inc. $1,500.00 06/22/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379395
Principal investigator 1 Exeltis, USA Inc. $5,500.00 06/22/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379981
Principal investigator 1 Exeltis, USA Inc. $450.00 06/15/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051378737
Principal investigator 1 Exeltis, USA Inc. $5,564.27 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379679
Principal investigator 1 Exeltis, USA Inc. $1,400.00 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379789
Principal investigator 1 Exeltis, USA Inc. $1,500.00 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379797
Principal investigator 1 Exeltis, USA Inc. $500.00 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380671
Principal investigator 1 Exeltis, USA Inc. $2,625.00 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380959
Principal investigator 1 Exeltis, USA Inc. $750.00 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381213
Principal investigator 1 Exeltis, USA Inc. $17,280.80 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381785
Principal investigator 1 Exeltis, USA Inc. $1,500.00 06/08/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381915
Principal investigator 1 Exeltis, USA Inc. $50.00 06/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381977
Principal investigator 1 Exeltis, USA Inc. $4,313.26 05/18/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381451
Principal investigator 1 Exeltis, USA Inc. $6,433.20 05/09/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381557
Principal investigator 1 Abbott Laboratories $250.00 05/03/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Specimen Collection Study from Women Referred to Coloscopy No dispute reported 06/30/2026 1039568613
Principal investigator 1 Abbott Laboratories $280.00 05/03/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039568643
Principal investigator 1 Exeltis, USA Inc. $130.50 05/02/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380307
Principal investigator 1 Exeltis, USA Inc. $50.00 05/01/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379547
Principal investigator 1 Abbott Laboratories $4,298.80 04/25/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039570319
Principal investigator 1 Exeltis, USA Inc. $11,758.40 04/20/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051378621
Principal investigator 1 Exeltis, USA Inc. $5,243.63 04/20/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380599
Principal investigator 1 Abbott Laboratories $34,390.40 04/10/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039568637
Principal investigator 1 Exeltis, USA Inc. $8,269.87 04/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381369
Principal investigator 1 Abbott Laboratories $8,597.60 04/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039568625
Principal investigator 1 Abbott Laboratories $6,720.00 04/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039570307
Principal investigator 1 Abbott Laboratories $104,245.90 04/05/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening No dispute reported 06/30/2026 1039570313
Principal investigator 1 Exeltis, USA Inc. $50.00 04/04/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051379559
Principal investigator 1 Exeltis, USA Inc. $130.50 04/03/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381033
Principal investigator 1 Organon LLC $546.00 03/28/2023 Non-covered Recipient Entity
Marvel Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016110915
Principal investigator 1 Sumitomo Pharma America, Inc. $7,238.00 03/23/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679915
Principal investigator 1 Sumitomo Pharma America, Inc. $748.00 03/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679897
Principal investigator 1 Sumitomo Pharma America, Inc. $480.00 03/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679903
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 03/16/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679909
Principal investigator 1 Exeltis, USA Inc. $1,195.20 03/09/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381693
Principal investigator 1 Exeltis, USA Inc. $150.00 03/07/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381807
Principal investigator 1 Exeltis, USA Inc. $300.00 03/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380747
Principal investigator 1 Exeltis, USA Inc. $3,208.50 03/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381721
Principal investigator 1 Sumitomo Pharma America, Inc. $773.00 02/23/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679883
Principal investigator 1 Sumitomo Pharma America, Inc. $6,327.00 02/23/2023 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1030679889
Principal investigator 1 Organon LLC $49.00 02/15/2023 Non-covered Recipient Entity
Wasatch Clinical Research
OG-6219-P001 No dispute reported 06/30/2026 1016111045
Principal investigator 1 Exeltis, USA Inc. $250.00 02/07/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381921
Principal investigator 1 Exeltis, USA Inc. $1,926.00 02/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380385
Principal investigator 1 Exeltis, USA Inc. $7,838.50 02/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381277
Principal investigator 1 Exeltis, USA Inc. $3,203.99 02/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381615
Principal investigator 1 Exeltis, USA Inc. $1,800.00 01/12/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381517
Principal investigator 1 Organon LLC $250.00 01/09/2023 Non-covered Recipient Entity
Sundance Clinical Research, LLC
OG-6219-P001 No dispute reported 06/30/2026 1016124485
Principal investigator 1 Exeltis, USA Inc. $6,770.23 01/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380801
Principal investigator 1 Exeltis, USA Inc. $900.00 01/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381327
Principal investigator 1 Exeltis, USA Inc. $565.20 01/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381411
Principal investigator 1 Exeltis, USA Inc. $2,200.00 01/06/2023 Non-covered Recipient Entity
TMC Life Research, Inc
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051381779
Principal investigator 1 Organon LLC $6,491.00 01/04/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
OG-6219-P001 No dispute reported 06/30/2026 1016081983
Principal investigator 1 Organon LLC $998.00 01/04/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
OG-6219-P001 No dispute reported 06/30/2026 1016081993
Principal investigator 1 Exeltis, USA Inc. $400.00 01/03/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380401
Principal investigator 1 Exeltis, USA Inc. $5,953.50 01/02/2023 Non-covered Recipient Entity
TMC Life Research, Inc.
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women No dispute reported 06/30/2026 1051380825